Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Rachel Ershler"'
Autor:
Urvi A. Shah, Karissa Whiting, Sean Devlin, Rachel Ershler, Bindu Kanapuru, David J. Lee, Sabrin Tahri, Thomas Gwise, Even H. Rustad, Sham Mailankody, Alexander M. Lesokhin, Dickran Kazandjian, Francesco Maura, Daniel Auclair, Brenda M. Birmann, Saad Z. Usmani, Nicole Gormley, Catherine R. Marinac, Ola Landgren
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-5 (2023)
Externí odkaz:
https://doaj.org/article/b9615b6311034833a6271e024f2e624b
Autor:
Andrea C. Baines, Maryam Sarraf Yazdy, Yvette L. Kasamon, Rachel Ershler, Emily Y. Jen, Bindu Kanapuru, Nicholas C. Richardson, Ashley Lane, Theresa Carioti, Marc R. Theoret, Richard Pazdur, Nicole J. Gormley
Publikováno v:
Clinical Cancer Research. :OF1-OF5
Minimal residual disease (MRD) is increasingly used as a prognostic biomarker, a measure of clinical efficacy, and a guide for treatment decisions in various hematologic malignancies. We sought to characterize MRD data in registrational trials in hem
Autor:
Bindu Kanapuru, Laura Fernandes, Andrea C Baines, Rachel Ershler, Vishal Bhatnagar, Elizabeth Pulte, Thomas Gwise, Marc R. Theoret, Richard Pazdur, Lola A. Fashoyin-Aje, Nicole Gormley
Publikováno v:
Blood Journal.
Narrow eligibility criteria may contribute to underrepresentation of racial and ethnic subgroups in cancer clinical trials. We conducted a retrospective pooled analysis of multicenter, global clinical trials submitted to the U.S. FDA between 2006-201
Autor:
Bindu Kanapuru, Laura L. Fernandes, Lola A. Fashoyin-Aje, Andrea C. Baines, Vishal Bhatnagar, Rachel Ershler, Thomas Gwise, Paul Kluetz, Richard Pazdur, Elizabeth Pulte, Yuan-Li Shen, Nicole Gormley
Publikováno v:
Blood Advances. 6:1684-1691
African Americans (AAs) have a higher incidence of multiple myeloma (MM) than White patients. Mortality is also higher in AAs compared with White patients. AAs more commonly have immunoglobulin H translocations t(11;14) and t(14;16) compared with Whi
FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Autor:
Andrea C. Baines, Rachel Ershler, Bindu Kanapuru, Qing Xu, Guoxiang Shen, Liang Li, Lian Ma, Olanrewaju O. Okusanya, Natalie E. Simpson, Wanda Nguyen, Marc R. Theoret, Richard Pazdur, Nicole J. Gormley
Publikováno v:
Clin Cancer Res
On August 5, 2020, the FDA granted accelerated approval to belantamab mafodotin-blmf (BLENREP; GlaxoSmithKline) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including
Autor:
Nicole J. Gormley, Peter M. Voorhees, Rachel Ershler, Shaji Kumar, Andrzej Jakubowiak, Marc R. Theoret, Andrea C. Baines, R. Pazdur, Bindu Kanapuru, Vishal Bhatnagar
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(1)
The multiple myeloma treatment landscape has evolved considerably over the last 20 years with the development of multiple therapies with novel mechanisms of action and new combination regimens. However, the recent failure of several large phase III t
Autor:
Marc R. Theoret, Yvette L. Kasamon, Andrea C. Baines, Emily Y. Jen, Rachel Ershler, Bindu Kanapuru, Nicholas Richardson, Theresa Carioti, Maryam Sarraf Yazdy, Ashley Lane, Nicole J. Gormley
Publikováno v:
Blood. 138:4928-4928
Introduction: In the past decade, multiple studies have reported the prognostic and predictive value of MRD status in specific hematologic malignancies (HM). Because clinical trials are increasingly incorporating MRD status as a biomarker and efficac
Autor:
Bindu Kanapuru, Nicole J. Gormley, Rachel Ershler, Richard Pazdur, Marc R. Theoret, Laura L. Fernandes, Paul G. Kluetz, Thomas Gwise
Publikováno v:
Journal of Clinical Oncology. 38:8543-8543
8543 Background: Obesity has been implicated as a risk factor for the development of certain types of cancers, including multiple myeloma. Previous studies in other tumor types suggest that overweight subjects may have better outcomes, however, in re
Autor:
Nicole J. Gormley, Ann T. Farrell, Richard Pazdur, Urvi A Shah, Yutao Gong, Bindu Kanapuru, Sham Mailankody, Marc R. Theoret, Rachel Ershler, Ola Landgren
Publikováno v:
Blood. 134:5505-5505
Background: Obesity has been implicated as a risk factor for the development of certain types of cancers, including multiple myeloma (Wallin 2011). In a report published in NEJM in 2016, the relative risk of multiple myeloma for overweight to class 1
Autor:
Diane E. Cole, Cody J. Peer, Brigitte C. Widemann, Lee J. Helman, David S. Schrump, Jeffrey Roth, William D. Figg, Rachel Ershler
Publikováno v:
Journal of Chromatography B. 970:95-101
Mithramycin is a neoplastic antibiotic synthesized by various Streptomyces bacteria. It is under investigation as a chemotherapeutic treatment for a wide variety of cancers. Ongoing and forthcoming clinical trials will require pharmacokinetic analysi